PENEM DERIVATIVES

Abstract: Compounds of the following formula I wherein X represent a sulphur or an oxygen atom, R is hydrogen or a C₁-C₄ alkyl group either unsubstituted or substituted by one or more substituents chosen from a free or protected hydroxy group and halogen atom; A is a Z, Z-O-CO- or -Z-CO- residue, wherein Z represents (a) an optionally substituted phenylene or naph­ thylene group, (b) an optionally substituted heterocyclediyl radical wherein the hetero ring is mono or bicyclic, saturated or unsaturated containing at least one heteroatom selected from the group of oxygen, sulphur and nitrogen; (c) an optionally substituted linear or branched C₁-C₇ alkylene radical; (d) a C₂-C₄ alkenylene or alkynylene group or a group of formula or (e) an optionally substituted C₃-C₈ cyclo­ alkylene ring; (f) an aralkylene radical of formula wherein n is 1, 2 or 3, and Q (+) represents a group, wherein (i) R₁, R₂, R₃ are independently an optionally substituted alkyl, aralkyl or aryl radical; or (ii) R₁ is as defined above under (i) and R₂, R₃ taken together with the nitrogen atom represent an optionally substituted heterocyclic or fused heterocyclic radical; or (iii) R₁, R₂, R₃, taken together with the nitrogen atom, repre­ sent an optionally substsituted azoniabicyclo or azonia­ tricyclo radical; or (iv) R₁, R₂, R₃, taken together with nitrogen atom, represent an optionally substituted pyridinium, pirazinium, pyrazo­ lium, or pyridazinium radical, such radicals being optio­ nally fused with one phenyl ring or with a 5-7 membered, saturated or unsaturated cycloaliphatic or heterocyclic ring, or a pharmaceutically or veterinarily acceptable salt thereof having high antibacterial activity.

Description: The present invention relates to new penem compounds, to processes for their preparation, and to pharmaceutical and veterinary compositions containing them. FR-A-2122196 relates to antibacterial carbapenem derivatives characterised by a 2-substituent of the formula: in which A represents cyclopentylene, cyclohexylene or C₂-C₆ alkylene optionally substituted by one or more C₁-C₄ alkyl groups; R⁵ represents either (a) an optionally substituted aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, aryl, araliphatic, heteroaryl, heteroaliphatic, heterocyclyl or heterocyclyl-aliphatic radical or (b) a divalent phenylene or C₁-C₄ alkylene group joined to the ring so as to form a bridged polycyclic group, and represents a quaternized nitrogen-containing non-aromatic heterocycle. The compounds of the invention are quaternary ammonium carboxylates of the following formula (Z) and their pharmaceutically or veterinarily acceptable salts: wherein X is sulphur or oxygen; R is hydrogen or unsubstituted C₁-C₄ alkyl or C₁-C₄ alkyl substituted by one or more substituents chosen from a free or protected hydroxy group and halogen atom; A is a -Z-, -Z-O-CO- or -Z-CO- residue, wherein Z is (a) unsubstituted or substituted phenylene or naphthylene; (b) unsubstituted or substituted furanediyl, 1 ,3-thiadiazolediyl, thiophenediyl or pyridinediyl; (c) unsubstituted or substituted linear or branched C₁-C₇ alkylene; (d) C₂-C₄ alkenylene or alkynylene or a group of formula (e) unsubstituted or substituted C₃-C₈ cycloalkylene; or (f) an aralkylene group of formula wherein n is 1, 2 or 3; Q (+) is a group, wherein (i) R₁, R₂ and R₃ are the same or different and each is unsubstituted or substituted C₁-C₄ alkyl, C₇-C₁₁ aralkyl, phenyl or naphthyl; or (ii) R₁ is as defined above under (i) and R₂ and R₃ together with the nitrogen atom form an unsubstituted or substituted heterocyclic or fused heterocyclic group wherein the heterocyclic ring is a 4 to 7 membered unsaturated ring which contains from 1 to 4 heteroatoms selected from oxygen, nitrogen and sulphur atoms; or (iii) R₁, R₂ and R₃ together with the nitrogen atom form an unsubstituted or substituted azoniabicyclo or azoniatricyclo radical; or (iv) R₁, R₂ and R₃ together with the nitrogen atom form an unsubstituted or substituted pyridinium, pyrazinium, pyrazolium, or pyridazinium group or such a group fused with a phenyl ring or with a 5 to 7 membered, saturated or unsaturated cycloaliphatic or heterocyclic ring wherein the heterocyclic ring contains from 1 to 4 heteroatoms selected from oxygen, nitrogen and sulphur atoms; and the substituents for the radicals mentioned in definitions (a) to (c) and (e) of Z and definitions (i) to (iv) of Q (+) being selected from (a ″) halogen; (b ″) hydroxy; (c ″) C₁-C₄ alkoxy; (d ″) C₁-C₄ alkylthio; (e ″) a group wherein each of R₄ and R₅ is, independently, hydrogen or C₁-C₄ alkyl; (f ″) sulfo; (g ″) -CO₂R₄ wherein R₄ is as defined above; (h ″) -C≡N; (i ″) dimethyl-formamidino; (j ″) a group wherein R₄ and R₅ are as defined above; (k ″) carbamoyloxy; (l ″) a hydroximinomethyl (HO-N=CH-) or methoximinomethyl (CH₃O-N=CH-) group; (m ″) a formamido or acetamido group; (n ″) a formyloxy or acetoxy group; (o ″) a C₁-C₄ alkanoyl group; (p ″) a phenyl or naphthyl group; (q ″) a saturated or unsaturated, 4 to 7 membered heterocyclic ring which contains from 1 to 4 heteroatoms selected from oxygen, nitrogen and sulphur atoms; (r ″) a nitro group; (s ″) a mesyloxy group; (t ″) an oxo group; and (u ″) a C₁-C₄ alkyl group either unsubstituted or substituted by a substituent chosen from (a ″) to (t ″) above. The present invention includes all the possible geometrical and optical isomers of the compounds of formula (I), either in the form of isomeric mixtures or in the form of the individual separated isomers. Preferably, the compounds of formula (I) have a (5R,6S) configuration. The preferred R group is an (α-hydroxy) ethyl radical and this radical preferably has a (1R) configuration, i.e. a R configuration at the α-carbon atom of the ethyl group. As already said also the pharmaceutically or veterinarily acceptable salts of the compounds of formula (I) are included within the scope of the invention. The said salts may be both salts with acids, either inorganic acids such as, e.g., acetic, citric, tartaric, fumaric or methanesulphonic acid, and salts with bases, either inorganic bases such as, e.g. alkali or alkaline-earth metal hydroxides, in particular sodium and potassium hydroxides, or organic bases such as, e.g., triethylamine, pyridine, benzylamine or collidine, including aminoacids such as, e.g., lysine or procaine. The invention includes also internal salts, i.e. zwitterions. In the present specification, the term "halogen" preferably encompasses fluorine and chlorine atom, but also iodine and bromine atoms. The alkyl groups, including the aliphatic moieties of the alkoxy, alkylthio and alkanoyl groups, may be branched or straight chain. A C₁-C₄ alkyl group is, preferably, methyl or ethyl. A C₁-C₇ alkylene radical is preferably methylene, ethylene, propylene or butylene group. A C₃-C₈ cycloalkylene ring is, preferably, cyclobutylene, cyclopentylene or cyclohexylene. A C₂-C₄ alkenylene group is, preferably, a 1,2-ethenylene. A C₂-C₄ alkynylene group is, preferably, ethynylene. The term "aryl" encompasses, preferably, phenyl and naphthyl groups. The heterocyclic rings may be saturated or unsaturated, may have from 4 to 7 members and may contain from 1 to 4 heteroatoms selected from oxygen, nitrogen and sulphur atom. A C₁-C₄ alkoxy group is, preferably, methoxy or ethoxy. A C₁-C₄ alkylthio group is, preferably, methylthio or ethylthio. A C₁-C₄ alkanoyl group is, preferably, acetyl or propionyl. A protected hydroxy group may be a hydroxy group protected by a protecting group chosen, for instance, from an optionally substituted, especially halo-substituted, acyl group, e.g., acetyl, monochloroacetyl, dichloroacetyl, trifluoroacetyl, benzoyl or p-bromophenacyl; a triarylmethyl group, in particular triphenylmethyl; a silyl group, in particular trimethylsilyl, dimethyl-tert-butylsilyl, diphenyl-tert-butyl silyl; or also a group such as tert-butoxy carbonyl, p-nitro-benzyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl, allyloxycarbonyl, benzyloxycarbonyl, and pyranyl. Preferred protecting groups of the hydroxy function are p-nitro-benzyloxycarbonyl; dimethyl-tert-butyl-silyl; diphenyl-tert-butyl-silyl; trimethyl silyl; allyloxy-carbonyl; benzyloxycarbonyl; p-bromo-phenacyl; triphenylmethyl and pyranyl. Preferred classes of compounds under this invention include compounds of formula (I) wherein : R is an (α-hydroxy)ethyl group; X is as defined above; Z is one of the following residues : (a') (b') (c') methylene, ethylene, n-propylene or tetramethylene group (d') 1,2 ethenediyl group (e') (f') para, meta or ortho Q (+) is wherein (i') R₁, R₂, R₃ are each independently methyl, ethyl, n-propyl, i -propyl, dimethylaminomethyl, cyanomethyl, cyanoethyl, carbamoylmethyl, 2-hydroxyethyl, 2-chloroethyl, carboxymethyl, ethoxycarbonylmethyl, carboxyethyl, 2-methyl-2-cyanoethyl, 3-oxobutyl or dimethylformimidino group or (ii') R₁ is as defined above under (i'), still preferably methyl, ethyl, chloroethyl, cyanomethyl, cyanoethyl, hydroxyethyl or aminoethyl, and R₂, R₃, taken together with the nitrogen atom, represent one of the following heterocyclyl ammonium radicals in said heterocyclic ring, when substituted, the substituents being one or more, preferably one or two, equal or different and selected from the group (a ″), (b ″), (e ″), (g ″), (h ″), (i ″), (q ″), (t ″) and (u ″) as defined above; or (iii') R₁, R₂, R₃, taken together with the nitrogen atom, represent one of the following radicals wherein the quinuclidine ring may be substituted by an oxo, hydroxy or methoxy group; or (iv') R₁, R₂, R₃, taken together with the nitrogen atom, represent one of the following radicals wherein R₆, R₇ are each independently hydrogen atom, C₁-C₄ alkyl, cyanomethyl or methylsulphonyl, carbamoyl, hydroxymethyl, methylthio, methoxy; and the pharmaceutically or veterinarily acceptable salts thereof. In general, preferred values for Z are those shown above under (a'), (c') and (e'). Also in general, preferred values for R₁, R₂ and R₃ are those shown above under (i'), (ii') and (iv'). Specific examples of preferred compounds of the invention are listed in the following table : The compounds of formula (I) and their pharmaceutically and veterinarily acceptable salts can be prepared by a process comprising reacting a compound of formula (II) wherein R₁, R₂, R₃ are as defined above, with a penem intermediate of formula (III) wherein R, X and A are as defined above, Z' is a carboxy protecting group, and L is a leaving group susceptible of nucleophilic displacement by the amine of formula (II), and then removing the protecting groups therein present and, if desired, converting an obtained compound of formula (I) into a said salt thereof and/or, if desired, separating a mixture of isomers of a compound of formula (I) or a said salt thereof into the single isomers. The leaving group L in the compound of formula (III) may be, for example, a sulphonyloxy group -OSO₂R', wherein R' is a substituted or unsubstituted alkyl or aryl group; or a halogen atom such as iodine, bromine, chlorine. A particularly preferred sulphonyloxy group is trifluoromethanesulphonyloxy, -OSO₂CF₃. A particularly preferred halogen atom is iodine. A carboxy protecting group Z' may be any group which, together with the -CO₂- moiety, forms an esterified carboxy group. Examples of carboxy protecting groups are, in particular, C₁-C₆ alkyl groups, for instance methyl, ethyl or tert-butyl; halo-substituted C₁-C₆ alkyl groups, for example 2,2,2-trichloroethyl; C₂-C₄ alkenyl groups, for example allyl; optionally substituted aryl groups, for example phenyl and p-nitro-phenyl; optionally substituted aryl C₁-C₆ alkyl groups, for example benzyl, p-nitro-benzyl and p-methoxy-benzyl; aryloxy-C₁-C₆ alkyl groups, for example phenoxy-ethyl; or groups such as benzhydryl, o -nitro-benzyhydryl, acetonyl, trimethylsilyl, diphenyl-tert-butyl-silyl, and dimethyl-tert-butyl-silyl, or groups such as pivaloyloxy methyl or phthalidyl. Particularly preferred carboxy protecting groups are allyl, p -nitrobenzyl, trimethylsilyl, dimethyl-tert-butyl-silyl, and trichloroethyl. When in the compound of formula (III) R is a C₁-C₃ alkyl group substituted by hydroxy, the hydroxy is preferably protected, and a particularly preferred protecting group is dimethyl-tert-butyl-silyl. The reaction between a compound of formula (II) and a compound of formula (III), may be performed in a suitable organic, preferably aprotic, solvent which may be, for instance, tetrahydrofuran, dimethylformamide, acetone or a halogenated hydrocarbon such as, e.g., dichloromethane. The reaction temperature may, preferably, vary between about -100°C and about +40°C, preferably between -70°C and +15°C. A compound of formula (III) wherein L is a sulphonyloxy group may be prepared reacting, according to known and conventional procedures, a carbinol precursor of formula (IV) wherein R, X, A and Z' are as defined above, with the appropriate sulphonyl anhydride or sulphonyl halide, preferably triflic anhydride, a triflic chloride, in the presence of a non-nucleophilic acid acceptor which may be, for instance, an inorganic base such as, e.g., calcium or lithium carbonate or calcium oxide, or an organic base such as, e.g., 2,6-lutidine or also the same compound of formula (II) to be reacted in the subsequent step. Indeed, according to a preferred procedure of the invention the compound of formula (IV) is made to react with the suitable sulphonyl anhydride or sulphonyl halide in the presence of an excess, usually an amount equal to or greater than 2 molar equivalents, of the desired compound of formula (II): in this situation the compound of formula (III) is not even isolated from the reaction mixture because it reacts in situ with the compound of formula (II). The hereabove said preferred procedure is preferably carried out using dry dichloromethane as solvent at temperatures from about -70°C to +25°C. When a compound of formula (II) is reacted with a compound of formula (III) wherein L is halogen, the presence of a silver salt particularly if soluble in the media, e.g. AgClO₄, may be beneficial. A compound of formula (III) wherein L is halogen, may be prepared from the corresponding carbinol precursor of formula (IV) according to a modified Mitsunobu reaction, according to which this carbinol is allowed to react with an organic amine hydrohalide, such as, for instance, methoxyamine hydrochloride, pyridine hydrochloride, pyridine hydrobromide and the preformed complex obtained from diethylazodicarboxylate and triphenylphosphine, said reaction being carried out, e.g., in tetrahydrofuran or methylene chloride, preferably around room temperature. Alternatively, in the above modified Mitsunobu reaction a zinc halide, such as zinc chloride, zinc bromide and zinc iodide, can be substituted for the organic amine hydrohalide, under conditions substantially similar to those reported in J. Org. Chem. , 1984, 49 , 3027. Alternatively, a compound of formula (III) wherein L is halogen may be obtained from the carbinol of formula (IV) according to the more conventional procedures, entailing reaction with inorganic acid halides such as SOCl₂, PCl₅, PCl₃, PBr₃, POCl₃, POBr₃ and the like. An additional methodology well-known in the literature, namely the reaction with PPh₃ in CCl₄, can be exploited for the preparation of compounds of formula (III) wherein L is chloride. A compound of formula (III) wherein L is iodine can be prepared by a halide exchange reaction from a compound of formula (III) wherein L is chlorine or bromine and sodium iodide, this reaction being preferably carried out in acetone at temperatures ranging from 0°C to + 60°C (reflux temperature). Some intermediates of formula (III), preferably when L is chlorine, and the intermediates of formula (IV), either as such or as their protected derivatives, are known compounds or can be prepared from known compounds by following known general methodologies. These include, for example, A) thermal cyclisation of a compound of formula (V) wherein R,X,A,Z' are as defined above, X' represents sulphur or oxygen, and W is free or protected OH, or halogen, preferably chlorine, according to the method described, for example, in J. Am. Chem. Soc. , 1978, 100 , 8214 and Chem. Pharm. Bull. , 1981, 29 , 3158; B) thermal cyclization of a compound of formula (VI) wherein R, X,X',A,Z' are as defined above, and W' is free or protected OH; said cyclisation being performed in the presence of an organic phosphite, preferably trimethyl or triethyl phosphite, according to the method described, for example in Chem. Pharm. Bull. , 1983, 31 , 768 and Tetrahedron Lett. , 1984, 25 , 2395; C) Condensation of a 2-thioxopenam of formula VII, either as such or in its thioenol form or as a salt thereof wherein R and Z' are as above described, with a reagent of formula (VIII) L -A-CH₂W' (VIII) wherein L, A and W' are as defined above, according to the method described, for example in J.Chem.Soc. , Chem.Comm ., 1982, 713; D) reaction of a 2-sulphinyl penem of formula (IX) wherein R, X' are as defined above, and R' is an optionally substituted alkyl, aryl or aralkyl, with a reagent of the formula (X) HS-A-CH₂W' (X) wherein A and W' are as defined above, according to the method described, for example, in Tetrahedron Lett ., 1982, 23 , 3535; E) cyclisation of a compound of formula (XI) wherein R, A, W, Z' are as defined above; said cyclisation occurring spontaneously, preferably in the presence of a mild base, following unmasking of the -SH moiety from a protected derivative thereof, according to the method described, for example, in J.Chem.Soc.,Chem.Commun ., 1983, 1005 ; F) reaction of a compound of formula (XII) wherein R, X, Z,Z' are as defined above with a carboxylic acid of formula (XIII), or an activated derivative thereof wherein W is as defined above, according to the method described, for example, in our British Patent Application No. 2,118,181 A. In particular, method A) may be used to obtain intermediates for formula (III) and (IV) wherein X represents a sulphur atom; methods B), C) and D) may be used to obtain intermediates of formula (IV) wherein X represents a sulphur atom; method E) may be used to obtain intermediates of formula (III) and (IV) wherein X represents an oxygen atom; method F) may be used to obtain intermediates of formula (III) and (IV) wherein - A - represents a group Removal of protecting groups can be effected by known per se procedures; e.g. silyl groups can be removed under mild acidic conditions, or by fluoride ions, e.g. with tetrabutylammonium fluoride; p-nitrobenzyl groups can be removed by reduction, e.g. by catalytic hydrogenation, or with metals, such as Fe and Zn; allyl carboxylates can be cleaved by transallylation with an organic acid or a salt thereof, such as acetic acid, 2-ethylhexanoic acid or their sodium and potassium salts, this reaction being catalyzed by a triphenylphosphine-palladium complex, preferably by tetrakis-triphenylphosphine-Pd°. The optional salification of an obtained compound and the separation of a mixture of isomers into the single isomers may be carried out following known and conventional procedures. Compounds of formula (II), (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII) and (XIII) are known compounds or can be prepared from known compounds according to known methods. The compounds of formula (I) and their pharmaceutically and veterinarily acceptable salts provided by the present invention are potent, broad spectrum antibacterial agents. In comparison with other penem compounds, e.g. the sodium salts derived from penems of formula (IV), or compounds of formula (I) wherein Q is an amine instead of quaternary ammonium, they usually show markedly increased in vitro activity against both Gram-positive and Gram-negative strains. Moreover, in comparison with other penem compounds, they show unusually prolonged plasma levels and, when tested in vivo after parenteral administration, they displayed a very high degree of therapeutic effectiveness in treating infections caused by both Gram-positive and Gram-negative bacteria, their toxicity being on the other hand quite negligible. The following table shows the activity of two typical compounds of formula (I), the Compounds (1) and (31) of the previous table Compound (1): (5R, 6S)-6-[(1R)-hydroxyethyl]-2-(2-pyridinio-ethylthio) penem-3-carboxylate (example 1) Compound (31): (5R, 6S)-6-[(1R)-hydroxyethyl]-2-[4-(pyridinio-methyl)phenoxy]penem-3-carboxylate (example 11). Owing to their high antibacterial activity the compounds of the invention are thus useful, for example, in the treatment of respiratory tract infections, for example, bronchitis, bronchopneumonia, pleuritis, hepatobiliary and abdominal infections, septicemia; urinary tract infections, for example, pyelonephritis, cystitis; obstetrical and gynecological infections, for instance, cervicitis, endometritis; ear, nose and throat infections, for instance otitis, sinusitis, parotitis. The invention further provides pharmaceutical and veterinary compositions comprising a suitable carrier and/or diluent and, as an active principle, a compound of the invention. The compounds of the invention may be administered, either to humans or to animals, in a variety of dosage forms, e.g., orally in the form of tablets, capsules, drops or syrups; rectally in the form of suppositories; parenterally, e.g., intravenously or intramuscularly (as solutions or suspensions), with intravenous administration being preferred in emergency situation; by inhalation in the form of areosols or solutions for nebulizers; intravaginally in the form, e.g., of pessaries; or topically in the form of lotions, creams and ointments. The pharmaceutical or veterinary compositions containing the compounds of the invention may be prepared in a conventional way by employing the conventional carriers or diluents used for, e.g., cephalosporins. Conventional carriers or diluents are, for example, water, gelatine, lactose, starches, magnesium stearate, talc, vegetable oils, cellulose and the like. Daily doses in the range of about 0.5 to about 100 mg per kg of body weight may be used, in various animal species, the exact dose depending on the age, weight and condition of the subject to be treated and on the frequency and route of administration. A preferred way of administration of the compounds of the invention is the parenteral one: in this case the compounds may be administered, for example to adult humans, in an amount ranging from about 250 mg to about 1000 mg pro dose , preferably about 500 mg pro dose , 1-4 times a day, dissolved in a suitable solvent, such as, for example, sterile water or lidocaine hydrochloride solution for intramuscolar injections, and sterile water, physiological saline solution, dextrose solution or the conventional intravenous fluids or electrolytes, for intravenous injections. Furthermore, the compounds of the invention may be used as antibacterial agents in a prophylactic manner, e.g., in cleaning or as surface disinfecting compositions, for example, at a concentration of about 0.2 to 1% by weight of such compounds admixed with, suspended or dissolved in conventional inert dry or aqueous carriers for application by washing or spraying. They are also useful as nutritional supplements in animal feeds. The following examples illustrate but do not limit the present invention. EXAMPLE 1 (5R, 6S)-6-[(1R)-hydroxyethyl]-2-(2-pyridinioethylthio)penem-3-carboxylate (Compound 1) A solution of 80% m-chloroperbenzoic acid (674 mg) in dichloromethane was added under stirring to a cooled (-20° C) solution of allyl (5R, 6S)-6-[(1R)-tert-butyldimethylsilyloxyethyl]-2-(ethylthio)-penem-3-carboxylate (0.88 g) in the same solvent (20 ml). After 20 minutes at -20° C, a further amount of the oxidant (50 mg) was added, the solvent removed in vacuo without external cooling and the residue passed through a SiO₂ column, eluting with ethyl acetate-cyclohexane mixtures, to obtain allyl (5R, 6S)-6-[(1R)-tert-butyldimethylsilyloxyethyl]-2-(ethylsulphynil)-penem-3-carboxylate as a syrup. This material (663 mg) was dissolved in acetonitrile and treated at -40° under nitrogen with 2-mercaptoethanol (0,14 ml) and diisopropylethylamine (0.25 ml), in this sequence. After 15 minutes at -40°, the reaction mixture was quenched with acetic acid and partitioned between water and ethyl acetate. The organic extracts were concentrated and the residue purified by flash chromatography thereby obtaining allyl (5R, 6S)-6-[(1R)-tert-butyldimethylsilyloxyethyl]-2-(2-hydroxyethylthio)-penem-3-carboxylate; IR = ν max (CHCl₃) s 3400, 1790, 1690 cm⁻¹; NMR(60 MH z , CDCl₃ +D₂O) = δ 0.06 (6H, s, SiMe₂), 0.85 (9H, s, SiBu t ), 1.25 (3H,d, J = 6.5 Hz, CH ₃CH), 3.10 (2H, t, J = 6 Hz, S CH ₂CH₂), 3.65 (1H, dd, J = 2 and 6 Hz, H-6), 3.80 (2H, t, J= 6 Hz, CH₂ CH ₂O), 4.2 (1H, m, CH₃ CH ), 4.75 (2H, br d, CO₂ CH ₂CH=), 5.1 and 5.3 (2H, each m, =CH₂), 5.60 (1H, d, J = 2 Hz, H-5), 5.7-6.2 (1H, m, CH =CH₂) ppm. Trifluoromethanesulphonic anhydride (0.44 ml) and pyridine (0.47ml) were added to a solution of the above intermediate (280 mg) in dry dichloromethane at -40° in an argon atmosphere. The reaction mixture was left rise at -15° and kept at this temperature until all the starting material had disappeared (TLC monitoring). A solution of 0.1M aqueous HCl (10 ml) was then added, the organic layer was separated, washed with a further amount of 0.1M HCl, dried and evaporated. The resulting residue, consisting of crude allyl (5R, 6S)-6-[(1R)-tert-butyldimethylsilyloxyethyl]-2-(2-pyridinioethylthio)-penem-3-carboxylate chloride, was immediately dissolved in tetrahydrofuran (20 ml) and stirred for 24 hours at room temperature in the presence of acetic acid (1 ml) and tetrabutylammonium fluoride trihydrate (1.5 g). The solvent was removed in vacuo and the residue was purified by silica gel chromatography, eluting in sequence with CH₂Cl₂, CH₂Cl₂-MeCN, and aqueous MeCN, thereby obtaining the allyl ester of the title product; IR = ν max (KBr) = 3400, 1785, 1690 cm⁻¹. This material (120 mg) was stirred for 30 minutes at room temperature under nitrogen in a mixture of triphenylphosphine (20 mg) tetrakis(triphenylphosphine) palladium (20 mg), and acetic acid (0.15 ml) in 1=1 tetrahydrofurandichloromethane (8 ml). After filtering the catalyst, the solvent was removed and the residue dissolved in demineralized water, washed with dichloromethane, and passed through a reserve-phase column (LiChroprep®RP-18 Merck, water and then 10% aq MeCN as eluants). The product containing fractions were collected and freeze-dried to give the title compound (40 mg) as a white powder; UV max (H₂O) 320 nm NMR (200 MHz, D₂O, 45°C)δ1.26 (3H,d, J =6.5 Hz); 3.4-3.8 (2H,m); 3.80 (1H,dd, J =1.6 and 6.1 Hz), 4.20 (1H,dq, J =6.1 and 6.5 Hz), 4.8-5.1 (2H,m), 5.33 (1H,d, J =1.6 Hz), 8.08 (2H,dd, J =6.6 and 7.8 Hz), 8.64(1H,t, J =7.8 Hz), 8.92 (2H,d, J =6.6 Hz). IR (KBr) δ max 1590, 1630, 1765 cm⁻¹. EXAMPLE 2 Operating as described in the previous example, the following compounds were analogously prepared : (5R,6S)-6-[(1R)-hydroxyethyl]-2-[-(3-methoxypyridinio)ethylthio]-penem-3-carboxylate (2); (5R,6S)-6-[(1R)-hydroxyethyl]-2-[2-(4-methylthiopyridinio)ethylthio]penem-3-carboxylate (3); (5R,6S)-6-[(1R)-hydroxyethyl]-2-[2-(3-methylthiopyridinio)ethylthio]penem-3-carboxylate (4); (5R,6S)-6-[(1R)-hydroxyethyl]-2-[2-(6,7-dihydro-5 H -cyclopenta[b] pyridinio)ethylthio]penem-3-carboxylate (5); (5R,6S)-6-[(1R)-hydroxyethyl]-2-[2-(N-methylpyrrolidinio)ethylthio]penem-3-carboxylate (6); (5R,6S)-6-[(1R)-hydroxyethyl]-2-[2-(N,N,N-trimethylammonio)ethylthio]penem-3-carboxylate (7); (5R,6S)-6-[(1R)-hydroxyethyl]-2-[2-(N-methylmorpholinio)ethylthio]penem-3-carboxylate (8); (5R,6S)-6-[(1R)-hydroxyethyl]-2-(3-pyridiniopropylthio)penem-3-carboxylate (9); (5R,6S)-6-[(1R)-hydroxyethyl]-2-[3-(N-methylpyrrolidinio)propylthio]penem-3-carboxylate (10); and (5R,6S)-6-[(1R)-hydroxyethyl]-2-(1-(N-methylpyrrolidinio)cyclopentyl]penem-3-carboxylate (11). EXAMPLE 3 (5R,6S)-6-[(1R)-hydroxyethyl]-2-[2-(3-methoxypyridinio)ethylthio]penem-3-carboxylate (Compound 2) . To a solution of allyl (5R,6S)-6-[(1R)-tert-butyldimethylsilyloxyethyl]-2-(2-hydroxyethylthio)penem-3-carboxylate (450 mg) in dry ethanol-free dichloromethane (15ml) there were added, at -30° under nitrogen, triethylamine (0.175 ml) and methane sulphonylchloride (0.09 ml). The progress of the reaction was monitored by TLC; when the starting material had disappeared, the reaction mixture was washed with diluted aq. NaHCO₃ and then with water. The organic phase was separated, dried over Na₂SO₄ evaporated to leave a residue which was purified by flash-chromatography (ethyl acetate-cyclohexane-mixtures), thereby obtaining allyl (5R,6S)-6-[(1R)-tert-butyldimethylsilyloxyethyl]-2-(2-methanesulphonyloxyethylthio)penem-3-carboxylate. This compound (436 mg) was immediately dissolved in dry acetone (25 ml) and heated under argon in the presence of sodium iodide (260 mg) at 40° for several hours. When the reaction was over (NMR monitoring), the solvent was evaporated and the residue partitioned between water and ethyl acetate. Removal of the solvent from the dried organic layer left a residue consisting of crude allyl (5R,6S)-6-[(1R)-hydroxyethyl]-2-(2-iodoethylthio)penem-3-carboxylate, which was used as such in the following step. A solution of the above intermediate in dry tetrahydrofuran (25 ml) was sequentially treated (ice-bath) with pyridine (0.2 ml) and silver perchlorate (175 mg). The reaction mixture was left rise to room temperature and the completition of the reaction was checked, at 30 minute intervals, by TLC. Most of the solvent was then removed in vacuo and the residue was taken up in CH₂Cl₂ and washed with cold 0.05M aqueous perchloric acid and then with water. The residue obtained from the dried organic layer was added to a solution of tetrabutylammonium fluoride trihydrate (1.7 g) in tetrahydrofuran (25 ml). Acetic acid (1 ml) was added and the mixture stirred overnight at room temperature Removal of the solvent and flash-chromatography over silica (CH₂Cl₂-MeCN, then aqueous MeCN) afforded a somewhat impure sample of the allyl ester of the title product, which was directly treated with triphenylphospine (30 mg), (PPh₃)₄Pd (30 mg) and acetic acid (0.3 ml) in a tetrahydrofuran-dichloromethane mixture. The progress of the reaction was monitored by TLC; further amounts of PPh₃ and of the catalyst (5 mg each) were added at 5 minute intervals until the starting material had disappeared. The catalyst was filtered off and the residue obtained upon evaporation was partitioned between water (1 ml) and dichloromethane (1 ml). The aqueous layer was collected and passed through a reverse-phase column, using water and finally aq. MeCN as eluants. Freeze-drying of the appropriate fractions gave the title compound (45 mg): IR :ν max (KBr) 3400, 1755, 1605 cm⁻¹; NMR (MH z , D₂O) : δ 1.31 (3H, d, J = 6.5 Hz CH ₃CH), 3.45 (2H, m, CH₂S), 3.97 (3H, s, OMe), 4.15 (1H, dd, J = 1.3 and 6 Mz, H-6), 4.4 (1H, m, CH₃C H ), 4.80 (2H, m, CH ₂N⁺), 5.70 (1H, d, J = 1.3 Hz, H-5), 7.7 - 8.2 (2H, m , 8.3-8.6 (2H, m, ppm. EXAMPLE 4 Operating as described in the previous example, the following compounds were analogously prepared : (5R,6S)-6-[(1R)-hydroxyethyl]-2-(2-pyridinioethylthio)penem-3-carboxylate (1); (5R,6S)-6-[(1R)-hydroxyethyl]-2-[2-(N-methylpyrrolidinio)ethylthio]penem-3-carboxylate (6); (5R,6S)-6-[(1R)-hydroxyethyl]-2-(3-pyridiniopropylthio)penem-3-carboxylate (9); and (5R,6S)-6-[(1R)-hydroxyethyl]-2-[3-(N-methylpyrrolidinio)propylthio]penem-3-carboxylate.(10). EXAMPLE 5 (5R,6S)-6-[(1R)-hydroxyethyl]-2-[2-(N-methylmorpholinio)ethylthio]penem-3-carboxylate. (Compound 8) A solution of allyl (5R, 6S)-6-[(1R)-tert-butyldimethylsilyloxyethyl]-2-(ethylsulphinyl)penem-3-carboxylate (prepared as described in Example 1) (230 mg) in dry acetonitrile (5ml) was cooled under argon to -60° and treated in sequence with N-(2-mercaptoethyl)-N-methylmorpholinio trifluoromethanesulphonate (176 mg) and diisopropylethylamine (0.12 ml). The reaction mixture was stirred for 30 minutes at -40° and then partitioned between 0.1N HCl and dichloromethane . The organic layer was washed with brine and the solvent removed , thus obtaining crude allyl (5R,6S)-6-[(1R)-tert-butyldimethylsilyloxyethyl]-2-[2-(N-methylmorpholinio)ethylthio]penem-3-carboxylate (chloride, trifluoromethanesulphonate salts) as a gum. This material was stirred with tetrabutylammonium fluoride trihydrate (470 mg) and acetic acid (0.5 ml) in tetrahydrofuran (10 ml) for 18 hours at room temperature. After evaporation of the solvent, the residue was loaded on a silica column. Elution with CH₂Cl₂, then CH₂Cl₂-EtOH, then EtOH-MeCN, and finally 35% aq. MeCN followed by removal of the solvent from the appropriate fractions, gave an aqueous solution of the allyl ester of the title product. After washing with ether and freeze-drying, the obtained powder was taken up in tetrahydrofuran dichloromethane (1:1, 10 ml), PPh₃ (50 mg) , (PPh₃)₄Pd (50 mg), and acetic acid (0.2 ml) were added, and the mixture stirred for 1 hour at room temperature. The catalyst was filtered off and the solvent evaporated. The residue was dissolved in demineralized water (1 ml), washed with ethyl acetate (1 ml), and the aqueous solution passed through a reverse phase column (LiChroprep®RP-18 Merck). Elution with water and then with acetonitrile-water, followed by freeze-drying of the appropriate fractions, gave the title product as a white powder (40 mg); IR : ν max (KBr) 3400, 1760, 1605, 1570 cm⁻¹; NMR (60 MHz, D₂O) : 1.29 (3H, d, J = 6.5 Hz, CH ₃CH), 3.2 (3H, s, CH₃N⁺), 3.1-4.1 (13H, m, CH₂S, morpholinio, CH₂⁺N and H-6), 4.25 (1H, m, CH₃- CH ), 5.75 (1H, d, J = 1.5 Hz, H-5) ppm. EXAMPLE 6 Operating as described in the previous example, the following compounds were analogously prepared : (5R,6S)-6-[(1R)-hydroxyethyl]-2-(2-pyridinioethylthio)penem-3-carboxylate (1); (5R,6S)-6-[(1R)-hydroxyethyl]-2-[2-(3-methylthiopyridinio)ethylthio]penem-3-carboxylate (4); (5R,6S)-6-[(1R)-hydroxyethyl]-2-[2-(N-methylpyrrolidinio)ethylthio]penem-3-carboxylate (6); and (5R,6S)-6-[(1R)-hydroxyethyl]-2-(3-pyridiniopropylthio)penem-3-carboxylate (9). EXAMPLE 7 (5R,6S)-6-[(1R)-hydroxyethyl]2-[4-(pyridiniomethyl)phenylthio]penem-3-carboxylate (Compound 12) A solution of allyl (5R,6S)-6-[(1R)-tert-butyldimethylsilyloxyethyl]-2-[4-(hydroxymethyl)phenylthio]penem-3-carboxylate (450 mg) in dry dichloromethane (20 ml) was stirred under argon with pyridine (0.7ml) and trifluoromethanesulphonic anhydride (0.66 ml) at -40°C for 30 minutes. The reaction mixture was poured into 0.1M HCl and the organic layer separated, washed with brine and evaporated. To the resulting gum there were added tetrahydrofuran (15 ml), acetic acid (1.5 ml), and tetrabutylammonium fluoride trihydrate (1.5 g). When the starting material had disappeared (TLC monitoring, about 1 day at room temperature), the solvent was evaporated in vacuo and the residue was purified by flash chromatography over SiO₂ (CH₂Cl₂-MeCN and then aqueous NeCN as eluants) to afford salts (chloride, acetate) of allyl (5R, 6S)-6-[(1R)-hydroxyethyl]-2-[4-(pyridiniomethyl)phenylthio]penem-3-carboxylate (220 mg) ; IR : ν max (film) : 3400, 1785, 1705 cm⁻¹. This material was taken up in a mixture of PPh₃ (23 mg), (PPh₃)₄ Pd (23 mg) and acetic acid (0.3 ml) in tetrahydrofuran-dichloroetane (1 : 1, 15 ml). More catalyst was added at ten minutes intervals, until the reaction was judged complete by TLC. The mixture was filtered, the solvent removed in vacuo and the residue purified by reverse-phase chromatography, eluting first with water and then with a gradient in acetonitrile. The β-lactam-containing fractions (UV >300nm) were collected and freeze-dried to give the title compound as a white amorphous solid (95 mg); IR :νmax (KBr) : 3400, 1760, 1600 cm⁻¹. EXAMPLE 8 Operating as described in the previous example, the following compounds were analogously obtained : (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(4-methylthiopyridiniomethyl)phenylthio]penem-3-carboxylate (13); (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(3-methoxypyridiniomethyl)phenylthio]penem-3-carboxylate (14); (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(3-methylthiopyridiniomethyl)phenylthio]penem-3-carboxylate (15); (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(2-methyl-5-ethylpyridiniomethyl)phenylthio]penem-3-carboxylate (16); (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(3-cyanomethylpyridiniomethyl)phenylthio]penem-3-carboxylate (19); (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(6,7-dihydro-5 H -cyclopenta[b]pyridiniomethyl)phenylthio]penem-3-carboxylate (20); (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(N-methylpyrrolidiniomethyl)phenylthio]penem-3-carboxylate (21); (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(N-methylpiperidiniomethyl)phenylthio]penem-3-carboxylate (22); (5R,6S)-6-[(1R)-hydroxyethyl)-2-[4-(N-methylmorpholiniomethyl)phenylthio]penem-3-carboxylate (23); (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(N,N,N-triethylammoniomethyl)phenylthio]penem-3-carboxylate (24); (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(N,N,N-trimethylammoniomethyl)phenylthio]penem-3-carboxylate (25); (5R,6S)-6-[(1R)-hydroxyethyl]-2-[2-(pyridiniomethyl)phenylthio]penem-3-carboxylate (26); (5R,6S)-6-[(1R)-hydroxyethyl]-2-[2-(N-methylpyrrolidiniomethyl)phenylthio]penem-3-carboxylate (27); (5R,6S)-6-[(1R)-hydroxyethyl]-2-[3-(pyridiniomethyl)phenylthio]penem-3-carboxylate (28); (5R,6S)-6-[(1R)-hydroxyethyl]-2-[3-(N-methylpiperidiniomethyl)phenylthio]penem-3-carboxylate (29) and, (5R,6S)-6-[(1R)-hydroxyethyl]-2-[3-(N,N,N-trimethylammoniomethyl)phenylthio]penem-3-carboxylate (30). EXAMPLE 9 (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(4-carbamoylpyridiniomethyl)phenylthio]penem-3-carboxylate (Compound 17). Allyl (5R,6S)-6-[(1R)-tert-butyldimethylsilyloxyethyl]-2-(4-hydroxymethylphenylthio)penem-3-carboxylate was converted into allyl (5R,6S)-6-[(1R)-tert-butyldimethylsilyloxyethyl]-2-(4-iodomethylphenylthio)penem-3-carboxylate by closely following the procedure described in Example 2. Without purification, this intermediate (250 mg) was dissolved in dry dimethylformamide and stirred at -20° under nitrogen with nicotinamide (500 mg) and silver perchlorate (120 mg). The reaction mixture was left to rise to room temperature while checking the progress of the reaction by TLC. Partition between dichloromethane and 0.05M aqueous hydrochloric acid followed by washing with water and brine of the organic layer, gave a solution of allyl (5R,6S)-6-[(1R)-tert-butyldimethylsilyloxyethyl]-2-[4-(4-carbamoylpyridiniomethyl)phenylthio]penem-3-carboxylate; IR : ν max (film) 1795, 1705 sh, 1685 cm⁻¹. Desilylation of this material with tetrabutylammonium fluoride followed by deallylation with (PPh₃)₄Pd, as indicated in Example 7, furnished the title compound; IR = ν max (KBr) : 3400, 1765, 1610 cm⁻¹. EXAMPLE 10 Operating as described in the previous example, the following compound was analogously obtained : (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(3-hydroxymethylpyridiniomethyl)phenylthio]penem-3-carboxylate (18). EXAMPLE 11 (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(pyridiniomethyl)phenoxy]penem-3-carboxylate (Compound 31) A solution of p-nitrobenzyl (5R,6S)-6-[(1R)-tert-butyldimethylsilyloxyethyl]-2-[4-(hydroxymethyl)phenoxy]penem-3-carboxylate (320 mg) in dry dichloromethane (15 ml) was cooled at -70° under nitrogen. Pyridine (1.5 ml) and trifluoromethanesulphonic anhydride (0.8 ml) were added in sequence, and the mixture left rise to -30°C. The reaction mixture was quenched with 0.1N aqueous HCl and the separated organic layer was washed once with water, then dried (Na₂SO₄), concentrated to a small volume and taken up in dry tetrahydrofuran (20 ml). To this solution, acetic acid (1 ml) and tetrabutylammonium fluoride trihydrate (1.0 g) was added, and the mixture stirred for 20 hours at room temperature. Removal of the solvent and flash-chromatography over silica (aq. MeCN) afforded the p-nitrobenzyl ester of the title product; IR ν max (film) 3400, 1790, 1710 cm⁻¹. This intermediate (200 mg) was taken up in a mixture of tetrahydrofuran (20 ml) and aq. NH₄Cl (5g in 20 ml). Iron powder (5g) was added and the mixture vigorously stirred at 10°-15° C until the reaction was judged complete by TLC (H₂O-MeOH-NaCl 9 : 1 : 1). The mixture was filtered, and the solvent was evaporated in vacuo to leave an aqueous solution of the crude title compound, which was isolated pure after reverse-phase chromatography (LiCroprep®RP-18 Merck) as a white powder (80 mg) ; IR : ν max (KBr) 3400, 1760, 1600 cm⁻¹. UV λ max (H₂O) 260, 303 nm NMR (200 MHz D₂O, 45°C) δ 1.33 (3H,d,J=6.5 Hz), 3.89 (1H,dd, J =1.6 and 6.1 Hz), 4.27 (1H,dq, J =6.1 and 6.5 Hz), 5.69 (1H,d, J =1.6Hz), 5.85 (2H,s), 7.54, 7.32 (each 2H,m), 8.13 (2H,dd, J =6.6 and 7.8 Hz), 8.62 (1H,t, J =7.8 Hz), 8.94 (2H,d, J =6.6 Hz). EXAMPLE 12 Operating as described in the previous example, the following compounds were analogously obtained : (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(3-cyanomethylpyridiniomethyl)phenoxy]penem-3 carboxylate (32); (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(3-methylthiopyridiniomethyl)phenoxy]penem-3-carboxylate (33); (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(3-methoxypyridiniomethyl)phenoxy]penem-3-carboxylate (34); (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(N,N,N-triethylammoniomethyl)phenoxy]penem-3-carboxylate (35); (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(N-methylpyrrolidiniomethyl)phenoxy]penem-3-carboxylate (36); (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(N-methylmorpholiniomethyl)phenoxy]penem-3-carboxylate (37); (5R,6S)-6-[(1R)-hydroxyethyl]-2-[2-(pyridiniomethyl)phenoxy]penem-3-carboxylate (38); and (5R,6S)-6-[(1R)-hydroxyethyl]-2-[3-(pyridiniomethyl)phenoxy]penem-3-carboxylate (39). (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(4-methoxypyridiniomethyl)phenoxy]penem-3-carboxylate (40); and (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(2-methoxypyridinio)phenoxy[penem-3-carboxylate (41).

Claims: Claims for the following Contracting States : BE, CH, DE, FR, GB, IT, LI, NL, SE A compound of formula (I): wherein X is sulphur or oxygen; R is hydrogen or unsubstituted C₁-C₄ alkyl or C₁-C₄ alkyl substituted by one or more substituents chosen from a free or protected hydroxy group and halogen atom; A is a -Z-, -Z-O-CO- or -Z-CO- residue, wherein Z is (a) unsubstituted or substituted phenylene or naphthylene; (b) unsubstituted or substituted furanediyl, 1,3-thiadiazolediyl, thiophenediyl or pyridinediyl; (c) unsubstituted or substituted linear or branched C₁-C₇ alkylene; (d) C₂-C₄ alkenylene or alkynylene or a group of formula (e) unsubstituted or substituted C₃-C₈ cycloalkylene; or (f) an aralkylene group of formula wherein n is 1, 2 or 3; Q (+) is a group, wherein (i) R₁, R₂ and R₃ are the same or different and each is unsubstituted or substituted C₁-C₄ alkyl, C₇-C₁₁ aralkyl, phenyl or naphthyl; or (ii) R₁ is as defined above under (i) and R₂ and R₃ together with the nitrogen atom form an unsubstituted or substituted heterocyclic or fused heterocyclic group wherein the heterocyclic ring is a 4 to 7 membered unsaturated ring which contains from 1 to 4 heteroatoms selected from oxygen, nitrogen and sulphur atoms; or (iii) R₁, R₂ and R₃ together with the nitrogen atom form an unsubstituted or substituted azoniabicyclo or azoniatricyclo radical; or (iv) R₁, R₂ and R₃ together with the nitrogen atom form an unsubstituted or substituted pyridinium, pyrazinium, pyrazolium, or pyridazinium group or such a group fused with a phenyl ring or with a 5 to 7 membered, saturated or unsaturated cycloaliphatic or heterocyclic ring wherein the heterocyclic ring contains from 1 to 4 heteroatoms selected from oxygen, nitrogen and sulphur atoms; and the substituents for the radicals mentioned in definitions (a) to (c) and (e) of Z and definitions (i) to (iv) of Q (+) being selected from (a ″) halogen; (b ″) hydroxy; (c ″) C₁-C₄ alkoxy; (d ″) C₁-C₄ alkylthio; (e ″) a group wherein each of R₄ and R₅ is, independently, hydrogen or C₁-C₄ alkyl; (f ″) sulfo; (g ″) -CO₂R₄ wherein R₄ is as defined above; (h ″) -C≡N; (i ″) dimethyl-formamidino; (j ″) a group wherein R₄ and R₅ are as defined above; (k ″) carbamoyloxy; (l ″) a hydroximinomethyl (HO-N=CH-) or methoximinomethyl (CH₃O-N=CH-) group; (m ″) a formamido or acetamido group; (n ″) a formyloxy or acetoxy group; (o ″) a C₁-C₄ alkanoyl group; (p ″) a phenyl or naphthyl group; (q ″) a saturated or unsaturated, 4 to 7 membered heterocyclic ring which contains from 1 to 4 heteroatoms selected from oxygen, nitrogen and sulphur atoms; (r ″) a nitro group; (s ″) a mesyloxy group; (t ″) an oxo group; and (u ″) a C₁-C₄ alkyl group either unsubstituted or substituted by a substituent chosen from (a ″) to (t ″) above; or a pharmaceutically or veterinarily acceptable salt thereof. A compound according to claim 1, wherein R is (α-hydroxy) ethyl. A compound according to claim 1 or claim 2 wherein Z is a group of the formula: A compound according to any one of the preceding claims wherein R₁, R₂ and R₃ are the same or different and each is methyl, ethyl, n-propyl, i -propyl, dimethylaminomethyl, cyanomethyl, cyanoethyl, carbamoylmethyl, 2-hydroxyethyl, 2-chloroethyl, carboxymethyl, ethoxycarbonylmethyl, carboxyethyl, 2-methyl-2-cyanoethyl, 3-oxobutyl or dimethylformamidino group A compound according to any one of claims 1 to 4 selected from (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(N,N,N-triethylammoniomethyl)phenylthio]penem-3-carboxylate; (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(N,N,N-trimethylammoniomethyl)phenylthio]penem-3-carboxylate; (5R,6S)-6-[(1R)-hydroxyethyl]-2-[3-(N,N,N-triethylammoniomethyl)phenylthio]penem-3-carboxylate; and (5R,6S)-[(1R)-hydroxyethyl]-2-[4-(N,N,N-triethylammoniomethyl)phenylthio]penem-3-carboxylate. A compound according to any one of claims 1 to 3, wherein R₁, R₂ and R₃ taken together with the nitrogen atom, represent one of the following radicals: wherein R₆ and R₇ are the same or different and each is hydrogen, C₁-C₄ alkyl, methoxy, methylthio, cyanomethyl, hydroxymethyl, methylsulphonyl or carbamoyl. A compound according to claim 6 selected from (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(pyridiniomethyl)phenylthio]penem-3-carboxylate; (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(4-methylthiopyridiniomethyl)phenylthio]penem-3-carboxylate; (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(3-methoxypyridiniomethyl)phenylthio]penem-3-carboxylate; (5R,6S)-6-[1R)-hydroxyethyl]-2-[4-(3-methylthiopyridiniomethylphenylthio]penem-3-carboxylate; (5R,6S)-6-[1R)-hydroxyethyl]-2-[4-(2-methyl-5-ethylpyridiniomethyl)phenylthio]penem-3-carboxylate; (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(4-carbamoylpyridiniomethyl)phenylthio]penem-3-carboxylate; (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(3-hydroxymethylpyridiniomethyl)phenylthio]penem-3-carboxylate; (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(3-cyanomethylpyridiniomethyl)phenylthio]penem-3-carboxylate; (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-_6,7-dihydro-5 H -cyclopenta [b]pyridiniomethyl)phenylthio]penem-3-carboxylate; (5R,6S)-6-[(1R)-hydroxyethyl]-2-[2-(pyridiniomethyl)phenylthio]penem-3-carboxylate; (5R,6S)-6-[(1R)-hydroxyethyl]-2-[3-(pyridiniomethyl)phenylthio]penem-3-carboxylate; (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(pyridiniomethyl)phenoxy]penem-3-carboxylate; (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(3-cyanomethylpyridiniomethyl)phenoxy]penem-3-carboxylate; (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(3-methylthiopyridiniomethyl)phenoxy]penem-3-carboxylate; (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(3-methoxypyridiniomethyl)phenoxy]penem-3-carboxylate; (5R,6S)-6-[(1R)-hydroxyethyl]-2-[2-(pyridiniomethyl)phenoxy]penem-3-carboxylate, and (5R,6S)-6-[(1R)-hydroxyethyl]-2-[3-(pyridiniomethyl)phenoxy]penem-3-carboxylate. A compound according to any one of claims 1 to 3 wherein R₁ is as defined in claim 4 and R₂ and R₃ together with the nitrogen atom, form a heterocyclyl ammonium group of formula: each of which groups is unsubstituted or substituted by one or more substituents selected from halogen, hydroxy, amino, cyano, dimethylformamidino, ethoxycarbonyl, a saturated or unsaturated, 4 to 7 membered heterocyclic ring which contains from 1 to 4 heteroatoms selected from oxygen, nitrogen and sulphur atoms, oxo, C₁-C₄ alkyl and alkanoyl. A compound according to claim 8 wherein R₁ is methyl, ethyl, chloroethyl, cyanomethyl, cyanoethyl, aminoethyl, or hydroxyethyl. A compound according to claim 9, selected from (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(N-methylpyrrolidiniomethyl)phenylthio]penem-3-carboxylate; (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(N-methylpiperidiniomethyl)phenylthio]penem-3-carboxylate; (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(N-methylmorpholiniomethyl)phenylthio]penem-3-carboxylate; (5R,6S)-6-[(1R)-hydroxyethyl]-2-[2-(N-methylpyrrolidiniomethyl)phenylthio]penem-3-carboxylate; (5R,6S)-6-[(1R)-hydroxyethyl]-2-[3-(N-methylpiperidiniomethyl)phenylthio]penem-3-carboxylate; (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-(N-methylpyrrolidiniomethyl)phenoxy]penem-3-carboxylate and (5R,6S)-6-[(1R)-hydroxyethyl]-2-[4-methylmorpholiniomethyl) phenoxy]penem-3-carboxylate. A compound according to claim 1 or claim 2, wherein Z is a group of formula: The compound (5R,6S)-6-[(1R)-hydroxyethyl]-2-[1-(N,-methylpyrrolidinio)cyclopentyl]penem-3-carboxylate. A compound according to claim 1 or claim 2, wherein Z is methylene, ethylene, n-propylene or tetramethylene. A compound according to claim 13 selected from (5R,6S)-6-[(1R)-hydroxyethyl]-2-(2-pyridinioethylthio)penem--3-carboxylate; (5R,6S)-6-[(1R)-hydroxyethyl]-2-[2-(3-methoxypyridinio)ethylthio]penem-3-carboxylate; (5R,6S)-6-[(1R)-hydroxyethyl]-2-[2-(4-methylthiopyridinio) ethylthio]penem-3-carboxylate; (5R,6S)-6-[(1R)-hydroxyethyl]-2-[2-(3-methylthiopyridinio)ethylthio]penem-3-carboxylate; (5R,6S)-6-[(1R)-hydroxyethyl]-2-[2-(6,7-dihydro-5 H -cyclopenta [b]pyridinio)ethylthio]penem-3-carboxylate; (5R,6S)-6-[(1R)-hydroxyethyl]-2-[2-(N-methylpyrrolidinio)ethylthio]penem-3-carboxylate; (5R,6S)-6-[(1R)-hydroxyethyl]-2-[2-(N,N,N-trimethylammonio)ethylthio]penem-3-carboxylate; (5R,6S)-6-[(1R)-hydroxyethyl]-2-[2-(N-methylmorpholinio)ethylthio]penem-3-carboxylate; (5R,6S)-6-[(1R)-hydroxyethyl]-2-(3-pyridiniopropylthio)penem-3-carboxylate; and (5R,6S)-6-[(1R)-hydroxyethyl]-2-[3-(N-methylpyrrolidinio)propylthio]penem-3-carboxylate. A process for the preparation of a compound of formula (I) according to claim 1 or a pharmaceutically or veterinarily acceptable salt thereof, the process comprising reacting a compound of formula (II) wherein R₁, R₂ and R₃ are as defined in claim 1, with a penem intermediate of formula (III) wherein R, X and A are as defined in claim 1, Z' is a carboxy protecting group, and L is a leaving group susceptible of nucleophilic displacement by the amine of formula (II), and then removing the protecting groups therein present and, if desired, converting an obtained compound of formula (I) into a said salt thereof and/or, if desired, separating a mixture of isomers of a compound of formula (I) or a said salt thereof into the single isomers. A process according to claim 15 wherein the intermediate of formula III is prepared by reacting a carbinol precursor of formula (IV) wherein R, X, A and Z' are as defined in claim 12, with a sulphonyl anhydride or sulphonyl halide in the presence of an excess of the compound of formula (II) without isolating said compound of formula (III) from the reaction mixture. A process according to claim 15 or claim 16 for producing a compound according to any one of claims 2 to 14. A pharmaceutical or veterinary composition comprising a suitable carrier and/or diluent and, as an active principle, a compound according to any one of claims 1 to 14 or a pharmaceutically or veterinarily acceptable salt thereof. A compound of formula (I) according to any one of claims 1 to 14 or a pharmaceutically or veterinarily acceptable salt thereof, for use in a method of treatment of the human or animal body by therapy. A compound or salt according to claim 19 for use as an antibacterial agent. Claims for the following Contracting State : AT A process for the preparation of a compound of formula (I): wherein X is sulphur or oxygen; R is hydrogen or unsubstituted C₁-C₄ alkyl or C₁-C₄ alkyl substituted by one or more substituents chosen from a free or protected hydroxy group and halogen atom; A is a -Z-, -Z-O-CO- or -Z-CO- residue, wherein Z is (a) unsubstituted or substituted phenylene or naphthylene; (b) unsubstituted or substituted furanediyl, 1,3-thiadiazolediyl, thiophenediyl or pyridinediyl; (c) unsubstituted or substituted linear or branched C₁-C₇ alkylene; (d) C₂-C₄ alkenylene or alkynylene or a group of formula (e) unsubstituted or substituted C₃-C₈ cycloalkylene; or (f) an aralkylene group of formula wherein n is 1, 2 or 3; Q (+) is a group, wherein (i) R₁, R₂ and R₃ are the same or different and each is unsubstituted or substituted C₁-C₄ alkyl, C₇-C₁₁ aralkyl, phenyl or naphthyl; or (ii) R₁ is as defined above under (i) and R₂ and R₃ together with the nitrogen atom form an unsubstituted or substituted heterocyclic or fused heterocyclic group wherein the heterocyclic ring is a 4 to 7 membered unsaturated ring which contains from 1 to 4 heteroatoms selected from oxygen, nitrogen and sulphur atoms; or (iii) R₁, R₂ and R₃ together with the nitrogen atom form an unsubstituted or substituted azoniabicyclo or azoniatricyclo radical; or (iv) R₁, R₂ and R₃ together with the nitrogen atom form an unsubstituted or substituted pyridinium, pyrazinium, pyrazolium, or pyridazinium group or such a group fused with a phenyl ring or with a 5 to 7 membered, saturated or unsaturated cycloaliphatic or heterocyclic ring wherein the heterocyclic ring contains from 1 to 4 heteroatoms selected from oxygen, nitrogen and sulphur atoms; and the substituents for the radicals mentioned in definitions (a) to (c) and (e) of Z and definitions (i) to (iv) of Q (+) being selected from (a ″) halogen; (b ″) hydroxy; (c ″) C₁-C₄ alkoxy; (d ″) C₁-C₄ alkylthio; (e ″) a group wherein each of R₄ and R₅ is, independently, hydrogen or C₁-C₄ alkyl; (f ″) sulfo; (g ″) -CO₂R₄ wherein R₄ is as defined above; (h ″) -C≡N; (i ″) dimethyl-formamidino; (j ″) a group wherein R₄ and R₅ are as defined above; (k ″) carbamoyloxy; (l ″) a hydroximinomethyl (HO-N=CH-) or methoximinomethyl (CH₃O-N=CH-) group; (m ″) a formamido or acetamido group; (n ″) a formyloxy or acetoxy group; (o ″) a C₁-C₄ alkanoyl group; (p ″) an aryl group; (q ″) a saturated or unsaturated, 4 to 7 membered heterocyclic ring which contains from 1 to 4 heteroatoms selected from oxygen, nitrogen and sulphur atoms; (r ″) a nitro group; (s ″) a mesyloxy group; (t ″) an oxo group; and (u ″) a C₁-C₄ alkyl group either unsubstituted or substituted by a substituent chosen from (a ″) to (t ″) above; or a pharmaceutically or veterinarily acceptable salt thereof, which process comprises reacting a compound of formula (II): wherein R₁, R₂ and R₃ are as defined above, with a penem intermediate of formula (III): wherein R, X and A are as defined above, Z' is a carboxy protecting group and L is a leaving group susceptible of nucleophilic displacement by the amine of formula (II); and then removing the protecting groups therein present and, if desired, converting an obtained compound of formula (I) into a said salt thereof and/or, if desired, separating a mixture of isomers of a compound of formula (I) or a said salt thereof into the single isomers. A process according to claim 1, wherein R is (α-hydroxy) ethyl. A process according to claim 1 or 2, wherein Z is a group of the formula: A process according to any one of the preceding claims, wherein R₁, R₂ and R₃ are the same or different and each is methyl, ethyl, n-propyl, i -propyl, dimethylaminomethyl, cyanomethyl, cyanoethyl, carbamoylmethyl, 2-hydroxyethyl, 2-chloroethyl, carboxymethyl, ethoxycarbonylmethyl, carboxyethyl, 2-methyl-2-cyanoethyl, 3-oxobutyl or dimethylformamidino group A process according to any one of claims 1 to 3, wherein R₁, R₂ and R₃, taken together with the nitrogen atom, represent one of the following radicals: wherein R₆ and R₇ are the same or different and each is hydrogen, C₁-C₄ alkyl, methoxy, methylthio, cyanomethyl, hydroxymethyl, methylsulphonyl or carbamoyl. A process according to any one of claims 1 to 3, wherein R₁ is as defined in claim 4 and R₂ and R₃, together with the nitrogen atom, form a heterocyclyl ammonium group of formula: each of which groups is unsubstituted or substituted by one or more substituents selected from halogen, hydroxy, amino, cyano, dimethylformamidino, ethoxycarbonyl, a saturated or unsaturated, 4 to 7 membered heterocyclic ring which contains from 1 to 4 heteroatoms selected from oxygen, nitrogen and sulphur atoms, oxo, C₁-C₄ alkyl and alkanoyl. A process according to claim 6, wherein R₁ is methyl, ethyl, chloroethyl, cyanomethyl, cyanoethyl, aminoethyl, or hydroxyethyl. A process according to claim 1 or 2, wherein Z is a group of formula: A process according to claim 1 or 2, wherein Z is methylene, ethylene, n-propylene or tetramethylene. A process according to any one of the preceding claims, wherein the intermediate of formula (III) is prepared by reacting a carbinol precursor of formula (IV) wherein R, X, A and Z' are as defined in claim 1, with a sulphonyl anhydride or sulphonyl halide in the presence of an excess of the compound of formula (II) without isolating said compound of formula (III) from the reaction mixture. A process according to any one of the preceding claims, further comprising forming a pharmaceutical or veterinary composition by formulating the compound of formula (I) or pharmaceutically or veterinarily acceptable salt thereof thus obtained with a suitable carrier and/or diluent.

Inventors: ALPEGIANI, MARCO, BEDESCHI, ANGELO, BRUNA, COSTANTINO DELLA, FRANCHESHI, GIOVANNI, PERRONE, ETTORE, ZARINI, FRANCO
Applicants: FARMITALIA CARLO ERBA S.R.L.
Application year: 1986
Main classification: C07D499
IPC codes: A61K31, C07D519, C07D499, A61P31